The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 16, 2018
Filed:
Nov. 19, 2015
Bristol-myers Squibb Company, Princeton, NJ (US);
Nils Lonberg, Woodside, CA (US);
Alan J. Korman, Piedmont, CA (US);
Bryan C. Barnhart, Philadelphia, PA (US);
Aaron P. Yamniuk, Lawrenceville, NJ (US);
Mohan Srinivasan, Cupertino, CA (US);
Karla A. Henning, Milpitas, CA (US);
Ming Lei, Princeton, NJ (US);
Emanuela Sega, Cupertino, CA (US);
Angela Goodenough, Morrisville, PA (US);
Maria Jure-Kunkel, Plainsboro, NJ (US);
Guodong Chen, East Brunswick, NJ (US);
John S. Sack, Lawrenceville, NJ (US);
Richard Y. Huang, Bridgewater, NJ (US);
Martin J. Corbett, Mount Holly, NJ (US);
Joseph E. Myers, Jr., Flemington, NJ (US);
Liang Schweizer, Shanghai PR, CN;
Sandra V. Hatcher, Hillsborough, NJ (US);
Haichun Huang, Fremont, CA (US);
Pingping Zhang, Cupertino, CA (US);
BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);
Abstract
The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.